Illumina (ILMN)
Supplies sequencing and array instruments, recurring consumables, informatics, and multiomics workflows.
Something off on this page? Send us feedback.
Sells sequencing and array instruments, consumables, informatics, and services to research and clinical customers worldwide. A broad installed base drives recurring flow-cell, reagent, library-preparation, and assay demand, while newer multiomics workflows extend the platform into methylation, single-cell analysis, and proteomics.
Builds sequencing and array platforms for research and clinical customers worldwide. Current lines include NovaSeq, NextSeq, MiSeq and iSeq sequencing families; Infinium arrays; library preparation and flow-cell consumables; and BaseSpace and DRAGEN informatics.
Links instruments to recurring consumables and software, so customer utilization of the installed base shapes demand for flow cells, reagents, kits, assays and service contracts. Newer workflows add methylation-aware DNA preparation, single-cell RNA analysis and NGS-read proteomics, including the SomaLogic portfolio.
Reports Core Illumina as one segment after spinning off GRAIL. Product availability varies by region and regulated-use status, and international access remains material. Instrument purchases in China still require government approval while the company remains on the Unreliable Entity List.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Upgrade | Target: $135 | Target: $260 |
| Sep 3, 2026 | Argus Research | Reiterate | Rating: —Target: $150 | Target: $235 |
| Aug 5, 2026 | Deutsche Bank | Downgrade | Rating: — | |
| Aug 3, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $190 | Target: $205 |
| Jul 31, 2026 | RBC Capital | Reiterate | Rating: —Target: $170 | Target: $230 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 28, 2026Cash & short-term investments $1.17B · Total debt $2.53B · Total assets $6.65B · Shareholders' equity $2.84B
- Revenue
- $1.16B
- Operating income
- $245.0M
- Net income
- $207.0M
No dividends on record.
| Institutions | ≥ 93.13% | 140.62M shares | |
|---|---|---|---|
| 967 holders · as of Jun 30, 2026 · largest filers only | |||
| Insiders | 0.86% | 1.30M shares | |
| 24 holders · as of Sep 10, 2026 | |||
| Other | ≤ 6.01% | 9.08M shares | |
| remainder | |||
151.00M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the 100 largest filers, so at least this.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 12.71% | 19.19M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 10.22% | 15.43M | as of Jun 30, 2026 |
Edgewood Management LLCInstitution | 5.79% | 8.74M | filed Feb 14, 2022 |
The Growth Fund of AmericaInstitution | 5.49% | 8.28M | filed Feb 14, 2017 |
Capital Research Global InvestorsInstitution | 5.29% | 7.99M | filed Feb 14, 2020 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Keith A. Meister | director | −119,501 | $218.40 |
| Sep 3, 2026 | Keith A. Meister | director | −75,951 | $218.23 |
| Sep 2, 2026 | Keith A. Meister | director | −68,108 | $213.28 |
| Aug 27, 2026 | Keith A. Meister | director | −138,379 | $228.89 |
| Aug 26, 2026 | Keith A. Meister | director | −106,543 | $225.46 |
- Thermo Fisher Scientific
Broad overlap in sequencing, genotyping arrays, and proteomics
- PacBio
HiFi long reads contest complex-genome and multiomic sequencing workloads
- Onterris
Real-time native DNA and RNA sequencing from portable to high-throughput
- 10x Genomics
Single-cell and spatial workflows overlap expanding multiomics offerings
- Agilent Technologies
Array and NGS-preparation rival in genotyping, cancer, and methylation
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Illumina | $246.55 | +3.24% | $36.13B | 44.6 | 43.2 | 8.0 | +9.4% |
| Thermo Fisher Scientific | $661.47 | +0.41% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| PacBio | $1.46 | +7.21% | $422.4M | — | — | 2.7 | −1.9% |
| Onterris | $16.78 | −4.00% | $631.7M | — | 81.5 | 0.8 | −20.4% |
| 10x Genomics | $81.43 | +2.95% | $10.04B | — | — | 16.3 | −12.7% |
| Agilent Technologies | $166.28 | +2.68% | $45.75B | 31.9 | 25.3 | 6.2 | +8.1% |
| Median | 33.7 | 25.3 | 5.3 | −1.9% |